Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 224

Results For "SEC"

2688 News Found

Cipla’s Q3FY22 PAT at Rs 729 cr.
News | January 26, 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.


Mandaviya reviews public health preparedness to Covid-19
Policy | January 26, 2022

Mandaviya reviews public health preparedness to Covid-19

Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation


Sanofi signs as first partner of Protas
Biotech | January 25, 2022

Sanofi signs as first partner of Protas

The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases


Agilent announces the Innovative Seahorse XF Pro Analyzer
Medical Device | January 25, 2022

Agilent announces the Innovative Seahorse XF Pro Analyzer

Optimized for pharma/biopharma to deliver a deeper understanding of cellular function


USFDA approves IND application for Allied’s cancer treatment
Biotech | January 24, 2022

USFDA approves IND application for Allied’s cancer treatment

APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types


Al-Futtaim partners with TytoCare to expand digital health services
Digitisation | January 24, 2022

Al-Futtaim partners with TytoCare to expand digital health services

Al-Futtaim will utilize TytoCare's TytoPro system in outpatient clinics around Dubai, providing patients with enhanced care and better access to specialists


Advent to acquire controlling stake in Avra Labs
News | January 24, 2022

Advent to acquire controlling stake in Avra Labs

Avra Labs is a Hyderabad based contract manufacturing and research services (CRAMs) and specialty active pharmaceutical ingredients (API) manufacturer with four facilities across the states of Telangana and Andhra Pradesh


Pfizer and OPKO update on the Biologics License Application for Somatrogon
Biotech | January 22, 2022

Pfizer and OPKO update on the Biologics License Application for Somatrogon

Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward


Molnupiravir reduces risk of hospitalisation by 30% : Dr Shashank Joshi
News | January 22, 2022

Molnupiravir reduces risk of hospitalisation by 30% : Dr Shashank Joshi

Omicron patients below 60 with no comorbidities can start treatment with paracetamol


Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
Drug Approval | January 21, 2022

Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir

The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list